Fresh off Kite and BeiGene deals, Shoreline ups the ante with a hefty crossover. But the biotech insists it’s in no rush

Though it may seem like Shoreline Biosciences is rapidly gaining momentum with a flurry of deals — and, now, a new funding round — Kleanthis Xanthopoulos doesn’t feel he’s in a rush.

The biotech’s chief executive put the bow on a $140 million Series B on Tuesday, as Shoreline...

Click to view original post